About Editorial team of BIPNs

Main team of content of bipns.com. Any type of content should be approved by us.
9 09, 2025

Solana price prediction eyes fresh highs while Remittix draws attention for faster breakout

By |2025-09-09T17:06:24+03:00September 9, 2025|Crypto News, News|0 Comments

The race for the best crypto to buy now has intensified this September as Solana continues a steady climb and new altcoins enter the spotlight.

Solana price predictions point to bullish momentum, yet it is Remittix that is stealing headlines as the PayFi challenger tipped for a faster breakout. 

The urgency is clear. Investors are watching closely and those who hesitate risk missing one of the most explosive opportunities of 2025.

Solana’s momentum: Price prediction and market outlook

News about - Solana price prediction eyes fresh highs while Remittix draws attention for faster breakout

Solana is trading around $207 and is strong enough to indicate that it will push to an upside of $213.62 by the month end. This is viewed by market analysts as a sign of strength in a fluctuating market and they believe that it will be able to stand its ground even should short-term shocks occur. 

Solana price predictions suggest that the token will remain between $205 and $213 in the coming weeks, underpinned by developer expansion and rising transaction volume. It is well positioned for steady gains, but investors searching for truly life-changing returns are already looking beyond Solana toward disruptive PayFi players promising rapid acceleration.

Remittix: The PayFi project investors cannot afford to miss

Remittix is not a speculative token. It is a utility-driven project that is already redefining how global payments work. Designed to let users send crypto and deliver fiat instantly into bank accounts across more than 30 countries, it tackles one of the biggest bottlenecks in finance.

News about - Solana price prediction eyes fresh highs while Remittix draws attention for faster breakout

This is not hype without substance. Remittix has sold over 645 million tokens at $0.103 and raised more than $24 million. The first centralized exchange listing on BitMart was secured after surpassing $20 million, while the second on LBank followed after the $22 million milestone. 

A third listing is being prepared and the wallet beta launch arrives in Q3 2025. Every catalyst is locked in, and early investors are running out of time.

Why Remittix is building momentum now:

  • Global Reach: Remittix enables crypto-to-bank transfers in 30 countries with no hidden fees.
  • Mobile Innovation: The Q3 2025 wallet beta will feature live FX conversion for user convenience.
  • Security and Trust: The platform has been audited by CertiK, building confidence in its foundation.
  • Liquidity Path: Confirmed listings on BitMart and LBank ensure visibility and investor access.

Delaying exposure to Remittix could cost investors their biggest breakout opportunity of 2025

Solana price predictions highlight a path of gradual strength, but the breakout narrative belongs to Remittix. It is rare to find a crypto project that delivers both real-world adoption and clear profit catalysts in one package. With listings secured, a wallet launch imminent and investor demand surging, Remittix looks set to outpace traditional altcoins.

Discover the future of PayFi with Remittix by checking out their project here:

Website: https://remittix.io   

Socials: https://linktr.ee/remittix   

$250,000 Giveaway: https://gleam.io/competitions/nz84L-250000-remittix-giveaway

News.Az 

Source link

9 09, 2025

Platinum price hits the initial target– Forecast today – 9-9-2025

By |2025-09-09T15:13:38+03:00September 9, 2025|Forex News, News|0 Comments


Platinum price returned to settle above $1382.00 level, increasing the efficiency of the bullish track, fluctuating near the initial target at $1400.00, the continuation of the attempts to provide positive momentum by the main indicators will increase the chances of resuming the bullish attack, to expect its rally towards $1412.00, then attempts to press on the barrier near $1435.00.

 

While the price return to settle below $1382.00 will force it to delay the bullish attack and form new correctional waves, which forces it to suffer some of the losses before resuming the main bullish attack by reaching $1362.00.

 

The expected trading range for today is between $1382.00 and $ 1412.00

 

Trend forecast: Bullish





Source link

9 09, 2025

The GBPJPY repeats the temporary negative stability– Forecast today – 9-9-2025

By |2025-09-09T15:12:34+03:00September 9, 2025|Forex News, News|0 Comments

Platinum price returned to settle above $1382.00 level, increasing the efficiency of the bullish track, fluctuating near the initial target at $1400.00, the continuation of the attempts to provide positive momentum by the main indicators will increase the chances of resuming the bullish attack, to expect its rally towards $1412.00, then attempts to press on the barrier near $1435.00.

 

While the price return to settle below $1382.00 will force it to delay the bullish attack and form new correctional waves, which forces it to suffer some of the losses before resuming the main bullish attack by reaching $1362.00.

 

The expected trading range for today is between $1382.00 and $ 1412.00

 

Trend forecast: Bullish



Source link

9 09, 2025

Woman hospitalised with serious symptoms after drinking matcha tea

By |2025-09-09T15:09:48+03:00September 9, 2025|Dietary Supplements News, News|0 Comments


Lynn has now quit her matcha habit and sticks to other types of tea

Lynn Shazeen in hospital on an IV drip

A woman was left on an IV drip in hospital with heart palpitations because of matcha tea. Lynn Shazeen, 28, began drinking matcha six months ago, having it at least once a week.

After three months, she started noticing unusual symptoms – fatigue, feeling cold and occasional heart palpitations. When she finally went to the hospital, blood tests showed her iron levels had nearly halved.

Doctors put her on a detox IV and prescribed iron supplements to restore her levels. Lynn, a nurse, said: “It was the only change I had made to my diet and daily routine. Myself and my doctor worked through every possibility but it became clear that the matcha was the cause.”

Woman hospitalised with serious symptoms after drinking matcha tea
Lynn Shazeen in hospital

Lynn is anemic, a condition where your blood doesn’t have enough healthy red blood cells to carry oxygen, so she’s had low iron before. She started drinking matcha on a regular basis six months ago as a way to introduce more anti-inflammatory elements into her diet.

Lynn said: “I had been dealing with some inflammation so my doctor had suggested that I adjust my diet. Matcha, and green tea in general, is known for its anti-inflammatory properties so I decided to start drinking one once a week or so.”

Three months into regularly drinking matcha, Lynn started to notice symptoms like increased fatigue, feeling cold and occasional heart palpitations. Over the next two weeks, the symptoms got progressively worse, so Lynn went to the hospital to have her blood work done, which is when she discovered the drop in her iron levels.

Lynn Shazeen says her matcha habit left her with heart palpitations
Lynn Shazeen says her matcha habit left her with heart palpitations

Research supported by the National Institutes of Health has found that green tea (including matcha) can interfere with the body’s absorption of iron from food. Tea contains natural compounds called catechins, which make it harder to take in iron – a key concern for people already at risk of low iron.

Lynn said: “I noticed I kept feeling a lot colder and more tired than usual but I had no idea what it was until I got the tests done. As soon as I saw that my iron levels had dropped from 23 to 13, I knew immediately that it was the matcha that had caused it.”

Lynn Shazeen drinking matcha
Lynn Shazeen drinking matcha

Realizing something as simple as a weekly matcha could have triggered her symptoms was a shock. She said: “It was a bit worrying, but as a health professional, I stayed calm. Since getting the IV, I’ve stopped drinking matcha and now only drink regular tea.

“I also take iron pills and vitamin C tablets to bring my levels back up.”



Source link

9 09, 2025

Dogecoin Price Prediction; Hedera (HBAR) Latest News & The Best Crypto To Buy Now For A 10x Multiplier

By |2025-09-09T15:04:59+03:00September 9, 2025|Crypto News, News|0 Comments

Dogecoin continues to dominate headlines with fresh accumulation signals, while Hedera (HBAR) struggles to break out of its sideways trading zone. Both tokens remain in focus as traders look for catalysts heading into the final stretch of the year.

Yet, growing buzz around Remittix, a new altcoin with real-world payment utility, has many calling it the best crypto to buy now for a potential 10x multiplier.

Dogecoin Price Prediction; Hedera (HBAR) Latest News & The Best Crypto To Buy Now For A 10x Multiplier

Dogecoin Price Prediction Strengthens With ETF Buzz Rising

Dogecoin is gaining momentum as capital flows shift in its favor, with traders eyeing the DOGE Price today as it consolidates under resistance. A steady rise in short-term holder supply shows retail investors are accumulating, a signal that has historically triggered explosive Dogecoin rallies. The DOGE News cycle has also been buzzing with anticipation of a Dogecoin ETF, with approval odds climbing across prediction markets. 

Remittix 547 1

Analysts now point to an expanding wedge pattern that could drive the Dogecoin Price Prediction as high as $1.40 before year-end. With speculation heating up, the Dogecoin Price could benefit from both accumulation trends and institutional products, making it one of the most-watched tokens in the market right now.

HBAR Price Consolidation Frustrates Traders Seeking A Breakout

Hedera Hashgraph is stuck in a tight range, with the HBAR Price today hovering near $0.2202 after weeks of sideways trading. Resistance at $0.2237 has capped upside attempts, while $0.2109 remains the key floor. Market signals point to indecision, as the RSI sits near neutral and volatility measures keep shrinking. This lack of conviction leaves traders waiting for a breakout. 

If buying demand accelerates, the HBAR Price Prediction points toward $0.2368 in the short term. A drop below support, however, could send the Hedera Price toward $0.1945. The current setup highlights how the market is in balance, with neither bulls nor bears taking control. For now, HBAR News centers on whether catalysts can push the Hedera Price Prediction higher.

Remittix Attracts Dogecoin And Hedera Holders Searching For Growth

Remittix

Remittix is winning attention as traders look beyond hype-driven tokens like PEPE and Pi Network. Priced at just $0.1050, RTX has raised more than $24.6 million while selling over 652 million tokens, showing strong investor conviction. 

Remittix offers a PayFi solution that lets users convert crypto into fiat instantly, making it one of the best cryptos to buy now for utility and growth. Its upcoming CEX listings and wallet beta launch add momentum that Dogecoin and Hedera holders are closely watching.

  • Over $24.6 million raised with more than 652 million tokens sold
  • Remittix Wallet beta testing begins September 15, 2025
  • BitMart confirmed as first CEX listing, with LBank next
  • Positioned as the best crypto to buy now under $1

With real adoption at its core, Remittix is emerging as a 10x contender for investors seeking value and long-term potential.

Discover the future of PayFi with Remittix by checking out their project here:

Website: https://remittix.io/ 

Socials: https://linktr.ee/remittix 

$250K Giveaway: https://gleam.io/competitions/nz84L-250000-remittix-giveaway

This article is not intended as financial advice. Educational purposes only.

Source link

9 09, 2025

Blockchain Game Alliance BGA Launches 2025 Web3 Gaming Survey for State of the Industry Report: Largest Industry Study, 5-Minute Entry and Prizes | Flash News Detail

By |2025-09-09T13:14:50+03:00September 9, 2025|News, NFT News|0 Comments


The Blockchain Game Alliance (BGA) has launched its annual State of the Industry Report 2025 survey, gathering insights from the Web3 and gaming ecosystems to shape the future of blockchain gaming. Announced by Sebastien Borget on September 6, 2025, this comprehensive survey invites participants to contribute their views in just five minutes, with enticing prizes including a Nintendo Switch and two €50 Amazon vouchers for those entering with a company email. As the largest industry-wide survey of its kind, it aims to define the trajectory of Web3 gaming, highlighting trends that could influence cryptocurrency markets tied to gaming tokens.

Web3 Gaming Survey Signals Bullish Momentum for Crypto Tokens

In the rapidly evolving world of Web3 gaming, this BGA survey represents a pivotal moment for traders eyeing opportunities in related cryptocurrencies. With blockchain gaming projected to drive significant adoption in the crypto space, insights from this report could reveal key developments in play-to-earn models, NFT integrations, and decentralized virtual economies. For instance, tokens like AXS from Axie Infinity and SAND from The Sandbox have historically surged during periods of heightened industry optimism. Traders should monitor these assets closely, as positive survey outcomes could trigger upward price movements. According to market analysts, the gaming sector’s growth correlates strongly with overall crypto market sentiment, potentially boosting trading volumes across major exchanges.

Focusing on trading strategies, consider the current market context where Web3 gaming tokens often exhibit volatility tied to ecosystem announcements. Without real-time data at this moment, historical patterns show that similar industry reports have led to 10-20% price increases in gaming cryptos within 24-48 hours post-release. For example, support levels for AXS have held steady around $5.50 in recent sessions, with resistance at $6.80, offering potential entry points for long positions if survey buzz builds momentum. Integrating on-chain metrics, such as increased transaction volumes on gaming platforms, can provide early signals for traders. This survey’s emphasis on ecosystem insights underscores the need for diversified portfolios that include gaming altcoins alongside blue-chip cryptos like BTC and ETH.

Cross-Market Correlations: Stock Influences on Web3 Gaming

From a broader trading perspective, Web3 gaming intersects with traditional stock markets, particularly through tech giants investing in metaverse and blockchain technologies. Companies like Roblox (RBLX) and Unity Software (U) have shown stock price correlations with crypto gaming trends, where positive Web3 developments often lift related equities. Traders can explore arbitrage opportunities by tracking how survey-driven optimism in Web3 spills over to stock indices like the Nasdaq, which has a heavy tech weighting. Institutional flows into gaming ETFs could amplify this effect, with recent data indicating a 15% uptick in venture capital funding for blockchain games in Q3 2025. This creates hedging strategies, such as pairing long positions in SAND with shorts on underperforming tech stocks during market dips.

Moreover, the survey’s focus on future directions in Web3 gaming invites analysis of AI integrations, which could propel AI-related tokens like FET or AGIX. As gaming ecosystems incorporate AI for enhanced player experiences, traders might see synergies boosting these assets. Market indicators suggest that trading volumes in AI cryptos rise by an average of 25% during gaming industry hype cycles. To optimize trades, watch for breakout patterns above key moving averages; for instance, ETH’s 50-day MA at $2,800 could serve as a pivot for gaming token rallies. Overall, this BGA initiative not only fosters community input but also positions traders to capitalize on emerging trends, blending insightful data with actionable market strategies for sustained profitability.

In summary, participating in the BGA State of the Industry Report 2025 survey offers more than just prizes—it’s a gateway to influencing and profiting from Web3 gaming’s evolution. With no real-time price fluctuations detailed here, the emphasis remains on sentiment-driven trading, where historical correlations point to potential gains in tokens like MANA and GALA. Traders are advised to stay vigilant, using tools like RSI indicators to gauge overbought conditions amid survey excitement. This development reinforces the interconnectedness of crypto and stock markets, promising exciting opportunities for those attuned to industry pulses.



Source link

9 09, 2025

Will $3,650 breakout push XAU/USD to $3,700?

By |2025-09-09T13:12:41+03:00September 9, 2025|Forex News, News|0 Comments


  • Gold consolidates just under $3,650 as traders weigh Fed cut odds and CPI/PPI catalysts.
  • Structural bids from central banks and geopolitical risk continue to underpin strength.
  • H4 Fair Value Gaps ($3,616–$3,645) define the battleground; breakout above $3,650 opens $3,700, breakdown risks $3,570.

Gold sustains record-high bid as rate-cut odds surge

Gold’s latest leg higher came on the back of a decisively weak U.S. August jobs report and a quick repricing toward a September Fed rate cut. Spot gold printed fresh records near $3,600/oz and continues to hover just below that line as traders firm up odds of easing at the upcoming FOMC. Lower policy-rate expectations compress real yields and keep the dollar on the defensive—classic tailwinds for bullion.

Beyond the macro rates impulse, the structural bid is alive: central-bank buying (with fresh headlines pointing to continued PBoC additions in August) and elevated geopolitical risk have reinforced gold’s role as a portfolio hedge. That backdrop helped absorb profit-taking dips into the back half of last week.

What’s driving Gold right now

  • Soft NFP seals the deal for September easing. August payrolls rose just 22k, and unemployment ticked up to 4.3%, pushing gold to new highs and cementing a 25 bp cut as the base case.
  • Markets sit near records; yields ease. Risk assets’ resilience alongside falling yields reflects a market leaning into easier policy—a mix that historically supports gold.
  • Central-bank demand & geopolitics. Reports of China’s PBoC adding to reserves and ongoing conflict risks keep strategic demand firm.

Price action follow-through: From forecast to $3,650 test

In Monday’s outlook, we highlighted gold’s ability to reclaim layered H4 Fair Value Gaps as a structural foundation for further upside. That forecast has since materialized: buyers defended the $3,550–$3,560 shelf, and momentum carried price into a clean breakout sequence.

The move extended into the $3,640–$3,650 zone, aligning with our projected bullish continuation path. Each retest of intraday imbalances attracted fresh demand, confirming market conviction that dips remain buying opportunities. The current structure shows price consolidating just under $3,650 – the next pivotal resistance before $3,700 comes into view.

CME FedWatch: 89% probability of September cut

The CME FedWatch Tool now prices an 89% probability of a 25 bp Fed rate cut at the September 17 meeting, with a smaller 10% chance of a 50 bp move.

This overwhelmingly dovish repricing is critical for gold. A confirmed rate cut would:

  • Lower U.S. real yields, directly reducing the opportunity cost of holding gold.
  • Weaken the U.S. dollar, reinforcing gold’s inverse correlation.
  • Strengthen haven demand, as easing signals the Fed’s recognition of slowing growth.

Together, these dynamics create a macro backdrop where gold’s floor remains supported, even if technicals temporarily stretch into overbought territory. Traders will watch whether CPI/PPI confirm the Fed’s dovish path—cool inflation could propel gold beyond $3,650 toward the $3,700 target zone.

Overall narrative: Why the bid can persist

Rate expectations are the beating heart of this move. With FedWatch showing nearly 90% odds of easing, gold has a clear policy-driven tailwind. Pair that with central-bank accumulation and risk-hedging flows, and dips have struggled to develop follow-through. If CPI/PPI confirm a cooling trend, the path of least resistance remains higher into the Fed meeting.

Technical outlook: XAU/USD still hot

Gold’s is consolidating beneath the $3,650 resistance, with multiple H4 Fair Value Gaps (FVGs) forming below current levels.

Prior to this move, the FVG at $3,630$3,616 served as a point-of-interest for bounce to the upside.

These FVGs between $3,616 – $3,645 are pivotal zones where buyers may attempt to step back in if price retraces. The reaction at these imbalances will dictate whether gold clears $3,650 for continuation or fades back into deeper retracement.

Bullish scenario: Reclaim above $3,650

The bullish case hinges on whether buyers can hold the FVGs and reclaim $3,650 with conviction.

  • Price dips into the $3,628–$3,638 FVG zone and finds strong buyer response.
  • A breakout and daily close above $3,650 confirms momentum continuation.
  • Upside targets: $3,670 first, then $3,700 psychological resistance.

Bearish scenario: Rejection and breakdown through FVGs

Alternatively, a sustained rejection under $3,650 combined with a hot CPI or stronger USD could trigger a deeper pullback.

  • Failure to reclaim $3,650 opens the path to revisit the FVGs.
  • A clean breakdown through the $3,628–$3,616 FVG cluster signals bearish intent.
  • Downside targets: $3,600, followed by $3,580–$3,570 where structural supports align.

Final note: Wait for confirmation

While both bullish and bearish paths are clear on the chart, gold is sitting at a pivotal juncture. With CPI/PPI ahead and Fed cut odds already priced, chasing moves without confirmation risks being trapped in volatility. Traders should wait for a confirmed breakout above $3,650 or a decisive breakdown through the $3,628–$3,616 zone before committing to directional trades.



Source link

9 09, 2025

The EURJPY failed to confirm the breach– Forecast today – 9-9-2025

By |2025-09-09T13:11:00+03:00September 9, 2025|Forex News, News|0 Comments

Platinum price returned to settle above $1382.00 level, increasing the efficiency of the bullish track, fluctuating near the initial target at $1400.00, the continuation of the attempts to provide positive momentum by the main indicators will increase the chances of resuming the bullish attack, to expect its rally towards $1412.00, then attempts to press on the barrier near $1435.00.

 

While the price return to settle below $1382.00 will force it to delay the bullish attack and form new correctional waves, which forces it to suffer some of the losses before resuming the main bullish attack by reaching $1362.00.

 

The expected trading range for today is between $1382.00 and $ 1412.00

 

Trend forecast: Bullish



Source link

9 09, 2025

Exercise and nutrition interventions for sarcopenia in cirrhosis: a systematic review and network meta-analysis of randomized controlled trials

By |2025-09-09T13:08:45+03:00September 9, 2025|Dietary Supplements News, News|0 Comments


  • Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650–66. https://doi.org/10.1016/j.cgh.2019.07.060.

    Article 
    PubMed 

    Google Scholar
     

  • Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharm Ther. 2020;51:64–77. https://doi.org/10.1111/apt.15571.

    Article 

    Google Scholar
     

  • Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.

    Article 
    PubMed 

    Google Scholar
     

  • Dhaliwal A, Armstrong MJ. Sarcopenia in cirrhosis: a practical overview. Clin Med. 2020;20:489–92. https://doi.org/10.7861/clinmed.2020-0089.

    Article 

    Google Scholar
     

  • Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLOS ONE. 2017;12:e0186990. https://doi.org/10.1371/journal.pone.0186990.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Merli M, Berzigotti A, Zelber-Sagi S, Dasarathy S, Montagnese S, Genton L, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–93.

    Article 

    Google Scholar
     

  • Bischoff SC, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr. 2020;39:3533–62.

    Article 
    PubMed 

    Google Scholar
     

  • Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1611–44. https://doi.org/10.1002/hep.32049.

    Article 
    PubMed 

    Google Scholar
     

  • Wolfe RR. Branched-chain amino acids and muscle protein synthesis in humans: myth or reality?. J Int Soc Sports Nutr. 2017;14:30. https://doi.org/10.1186/s12970-017-0184-9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. Transl Gastroenterol Hepatol. 2018;3:47. https://doi.org/10.21037/tgh.2018.07.06.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84. https://doi.org/10.7326/M14-2385.

    Article 
    PubMed 

    Google Scholar
     

  • Senn SS. Cross-over trials in clinical research. John Wiley & Sons; 2002.

  • Suzuki K, Endo R, Kohgo Y, Ohtake T, Ueno Y, Kato A, et al. Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma. Hepatol Res. 2012;42:621–6. https://doi.org/10.1111/j.1872-034X.2012.00990.x.

    Article 
    PubMed 

    Google Scholar
     

  • Bohannon RW. Considerations and practical options for measuring muscle strength: a narrative review. BioMed Res Int. 2019;2019:8194537.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Manini TM, Visser M, Won-Park S, Patel KV, Strotmeyer ES, Chen H, et al. Knee extension strength cutpoints for maintaining mobility. J Am Geriatrics Soc. 2007;55:451–7.

    Article 

    Google Scholar
     

  • Hari A. Muscular abnormalities in liver cirrhosis. World J Gastroenterol. 2021;27:4862–78. https://doi.org/10.3748/wjg.v27.i29.4862.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen HW, Ferrando A, White MG, Dennis RA, Xie J, Pauly M, et al. Home-based physical activity and diet intervention to improve physical function in advanced liver disease: a randomized pilot trial. Dig Dis Sci. 2020;65:3350–9. https://doi.org/10.1007/s10620-019-06034-2.

    Article 
    PubMed 

    Google Scholar
     

  • Laboratories ACoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.

    Article 

    Google Scholar
     

  • Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatrics Soc. 1991;39:142–8.

    Article 

    Google Scholar
     

  • Van Kan GA, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009;13:881–9. https://doi.org/10.1007/s12603-009-0246-z.

    Article 

    Google Scholar
     

  • Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38:485–521. https://doi.org/10.1016/j.clnu.2018.12.022.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLOS Med. 2020;17:e1003082. https://doi.org/10.1371/journal.pmed.1003082.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60. https://doi.org/10.1136/ebmental-2019-300117.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rücker G, König J, Krahn U, Efthimiou O, Davies A, Papakonstantinou T, et al. Package ‘netmeta’. Network meta-analysis using frequentist methods. netmeta.

  • Dias S, Caldwell DM. Network meta-analysis explained. Arch Dis Child—Fetal Neonatal Ed. 2019;104:F8. https://doi.org/10.1136/archdischild-2018-315224.

    Article 
    PubMed 

    Google Scholar
     

  • Rücker G, Petropoulou M, Schwarzer G. Network meta-analysis of multicomponent interventions. Biometrical J. 2020;62:808–21. https://doi.org/10.1002/bimj.201800167.

    Article 

    Google Scholar
     

  • Bell ML, Kenward MG, Fairclough DL, Horton NJ. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. Bmj. 2013;346:e8668. https://doi.org/10.1136/bmj.e8668.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Les I, Doval E, García-Martínez R, Planas M, Cárdenas G, Gómez P, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106:1081–8. https://doi.org/10.1038/ajg.2011.9.

    Article 
    PubMed 

    Google Scholar
     

  • Aamann L, Dam G, Borre M, Drljevic-Nielsen A, Overgaard K, Andersen H, et al. Resistance training increases muscle strength and muscle size in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2020;18:1179–87.e6. https://doi.org/10.1016/j.cgh.2019.07.058.

    Article 
    PubMed 

    Google Scholar
     

  • Lattanzi B, Bruni A, Di Cola S, Molfino A, De Santis A, Muscaritoli M, et al. The effects of 12-week beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: results from a randomized controlled single-blind pilot study. Nutrients. 2021;13. https://doi.org/10.3390/nu13072296.

  • Singh Tejavath A, Mathur A, Nathiya D, Singh P, Raj P, Suman S, et al. Impact of branched chain amino acid on muscle mass, muscle strength, physical performance, combined survival, and maintenance of liver function changes in laboratory and prognostic markers on sarcopenic patients with liver cirrhosis (BCAAS Study): a randomized clinical trial. Front Nutr. 2021;8:715795. https://doi.org/10.3389/fnut.2021.715795.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mohta S, Anand A, Sharma S, Qamar S, Agarwal S, Gunjan D, et al. Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia. Hepatol Int. 2022;16:680–90. https://doi.org/10.1007/s12072-022-10334-7.

    Article 
    PubMed 

    Google Scholar
     

  • Sirisunhirun P, Bandidniyamanon W, Jrerattakon Y, Muangsomboon K, Pramyothin P, Nimanong S, et al. Effect of a 12-week home-based exercise training program on aerobic capacity, muscle mass, liver and spleen stiffness, and quality of life in cirrhotic patients: a randomized controlled clinical trial. BMC Gastroenterol. 2022;22:66. https://doi.org/10.1186/s12876-022-02147-7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Román E, Torrades MT, Nadal MJ, Cárdenas G, Nieto JC, Vidal S, et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci. 2014;59:1966–75. https://doi.org/10.1007/s10620-014-3086-6.

    Article 
    PubMed 

    Google Scholar
     

  • Román E, García-Galcerán C, Torrades T, Herrera S, Marín A, Doñate M, et al. Effects of an exercise programme on functional capacity, body composition and risk of falls in patients with cirrhosis: a randomized clinical trial. PLoS One. 2016;11:e0151652. https://doi.org/10.1371/journal.pone.0151652.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zenith L, Meena N, Ramadi A, Yavari M, Harvey A, Carbonneau M, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1920–6.e2. https://doi.org/10.1016/j.cgh.2014.04.016.

    Article 
    PubMed 

    Google Scholar
     

  • Kruger C, McNeely ML, Bailey RJ, Yavari M, Abraldes JG, Carbonneau M, et al. Home exercise training improves exercise capacity in cirrhosis patients: role of exercise adherence. Sci Rep. 2018;8:99. https://doi.org/10.1038/s41598-017-18320-y.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Simko V. Long-term tolerance of a special amino acid oral formula in patients with advanced liver disease. Nutr Rep Int. 1983;27:765–73.


    Google Scholar
     

  • Tangkijvanich P, Mahachai V, Wittayalertpanya S, Ariyawongsopon V, Isarasena S. Short-term effects of branched-chain amino acids on liver function tests in cirrhotic patients. Southeast Asian J Trop Med Public Health. 2000;31:152–7.

    PubMed 

    Google Scholar
     

  • Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124:1792–801. https://doi.org/10.1016/s0016-5085(03)00323-8.

    Article 
    PubMed 

    Google Scholar
     

  • Nakaya Y, Okita K, Suzuki K, Moriwaki H, Kato A, Miwa Y, et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition. 2007;23:113–20. https://doi.org/10.1016/j.nut.2006.10.008.

    Article 
    PubMed 

    Google Scholar
     

  • Sorrentino P, Castaldo G, Tarantino L, Bracigliano A, Perrella A, Perrella O, et al. Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. J Gastroenterol Hepatol. 2012;27:813–22. https://doi.org/10.1111/j.1440-1746.2011.07043.x.

    Article 
    PubMed 

    Google Scholar
     

  • Ruiz-Margáin A, Macías-Rodríguez RU, Ríos-Torres SL, Román-Calleja BM, Méndez-Guerrero O, Rodríguez-Córdova P, et al. Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis. Rev Gastroenterol Mex (Engl Ed). 2018;83:9–15. https://doi.org/10.1016/j.rgmx.2017.02.005.

    Article 
    PubMed 

    Google Scholar
     

  • Hernández-Conde M, Llop E, Gómez-Pimpollo L, Fernández Carrillo C, Rodríguez L, Van Den Brule E, et al. Adding branched-chain amino acids to an enhanced standard-of-care treatment improves muscle mass of cirrhotic patients with sarcopenia: a placebo-controlled trial. Am J Gastroenterol. 2021;116:2241–9. https://doi.org/10.14309/ajg.0000000000001301.

    Article 
    PubMed 

    Google Scholar
     

  • Maharshi S, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol. 2016;14:454–60.e3. https://doi.org/10.1016/j.cgh.2015.09.028.

    Article 
    PubMed 

    Google Scholar
     

  • Sobhy E, Kamal MM, Saad Y, Saleh DA, Elgohary R, Hassan MS. Effect of branched-chain amino acid supplementation and exercise on quadriceps muscle quantity and quality in patients with cirrhosis as assessed by ultrasonography: a randomized controlled trial. Clin Nutr ESPEN. 2024;61:108–18. https://doi.org/10.1016/j.clnesp.2024.03.011.

    Article 
    PubMed 

    Google Scholar
     

  • Hey P, Hoermann R, Sinclair M, Chapman B, Testro A, Apostolov R, et al. Branched-chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: results of a randomised controlled trial. Alimentary Pharm Therapeutics. 2024;59:941–52. https://doi.org/10.1111/apt.17917.

    Article 

    Google Scholar
     

  • Meena BL, Taneja S, Tandon P, Sahni N, Soundararajan R, Gorsi U, et al. Home-based intensive nutrition therapy improves frailty and sarcopenia in patients with decompensated cirrhosis: a randomized clinical trial. J Gastroenterol Hepatol. 2023;38:210–8. https://doi.org/10.1111/jgh.16035.

    Article 
    PubMed 

    Google Scholar
     

  • Siramolpiwat S, Limthanetkul N, Pornthisarn B, Vilaichone R-k, Chonprasertsuk S, Bhanthumkomol P, et al. Branched-chain amino acids supplementation improves liver frailty index in frail compensated cirrhotic patients: a randomized controlled trial. BMC Gastroenterol. 2023;23:154. https://doi.org/10.1186/s12876-023-02789-1.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Higgins JP, Altman DG. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: Cochrane Book Series. 2008:187–241.

  • Tipton KD, Wolfe RR. Exercise, protein metabolism, and muscle growth. Int J Sport Nutr Exerc Metab. 2001;11:109–32. https://doi.org/10.1123/ijsnem.11.1.109.

    Article 
    PubMed 

    Google Scholar
     

  • Fujita S, Volpi E. Amino acids and muscle loss with aging. J Nutr. 2006;136:277S–80S. https://doi.org/10.1093/jn/136.1.277S.

    Article 
    PubMed 

    Google Scholar
     

  • Fox R, Stenning K, Slee A, Macnaughtan J, Davies N. Sarcopenia in liver cirrhosis: Prevalence, pathophysiology and therapeutic strategies. Anal Biochem. 2022;647:114581. https://doi.org/10.1016/j.ab.2022.114581.

    Article 
    PubMed 

    Google Scholar
     

  • Chu SF, Liou TH, Chen HC, Huang SW, Liao CD. Relative efficacy of weight management, exercise, and combined treatment for muscle mass and physical sarcopenia indices in adults with overweight or obesity and osteoarthritis: a network meta-analysis of randomized controlled trials. Nutrients. 2021;13. https://doi.org/10.3390/nu13061992.

  • Negm AM, Lee J, Hamidian R, Jones CA, Khadaroo RG. Management of sarcopenia: a network meta-analysis of randomized controlled trials. J Am Med Dir Assoc. 2022;23:707–14. https://doi.org/10.1016/j.jamda.2022.01.057.

    Article 
    PubMed 

    Google Scholar
     

  • Meyer F, Bannert K, Wiese M, Esau S, Sautter LF, Ehlers L, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci 2020;21. https://doi.org/10.3390/ijms21155357.

  • EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172-93. https://doi.org/10.1016/j.jhep.2018.06.024.

  • Schwarzer G, Carpenter JR, Rücker G. Small-study effects in meta-analysis. In: Schwarzer G, Carpenter JR, Rücker G, editors. Meta-Analysis with R, Cham: Springer International Publishing; 2015, p. 107–41. https://doi.org/10.1007/978-3-319-21416-0_5.

  • Suchomel TJ, Nimphius S, Stone MH. The importance of muscular strength in athletic performance. Sports Med. 2016;46:1419–49. https://doi.org/10.1007/s40279-016-0486-0.

    Article 
    PubMed 

    Google Scholar
     

  • Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, et al. Exercise in cirrhosis: translating evidence and experience to practice. J Hepatol. 2018;69:1164–77. https://doi.org/10.1016/j.jhep.2018.06.017.

    Article 
    PubMed 

    Google Scholar
     

  • Chen L-K, Woo J, Assantachai P, Auyeung T-W, Chou M-Y, Iijima K, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J American Med Directors Assoc. 2020;21. https://doi.org/10.1016/j.jamda.2019.12.012.



  • Source link

    9 09, 2025

    Cardano Price Prediction: Falling Wedge Setup Points to $0.95 Move if ADA Bulls Reclaim $0.84 Resistance

    By |2025-09-09T13:02:47+03:00September 9, 2025|Crypto News, News|0 Comments

    Cardano hovers near $0.83, pressing against a key breakout level at $0.84 as participants anticipate its next decisive move.

    Cardano is currently trading at $0.83, up 1.20% in the last 24 hours, as momentum slowly starts to build around the altcoin. After weeks of consolidation, ADA is showing signs of strength, with participants watching closely for a breakout setup that could set the tone for its next major move.

    Cardano price is trading around $0.83, up 1.94% in the last 24 hours. Source: Brave New Coin

    Cardano Positioned to Shine as Altseason Nears

    The Altcoin Season Index is climbing toward the critical threshold, currently sitting at 65, suggesting the market may soon move into a true altseason phase. Historically, this level has acted as a precursor for capital rotation out of Bitcoin and into alternative assets. Cardano, with its consistent developer activity and long-term community support, stands out as one of the coins that could capture significant inflows once this rotation gains pace.

    Cardano Price Prediction: Falling Wedge Setup Points to alt=

    Cardano eyes altseason momentum as the index nears a critical threshold, positioning it among top Layer 1 contenders. Source: Raphael Turcios via X

    For ADA, the timing is particularly important. After months of consolidation and steady upgrades to its ecosystem, the coin is well-positioned to benefit from a wave of renewed interest in altcoins. If the index continues pushing towards the upper zone above 75, it could set the stage for broader momentum across major Layer 1 assets, with Cardano likely to be one of the prime beneficiaries.

    Cardano Price Outlook Ahead of September Decisions

    Cardano is trading around $0.83, holding firm above the 50-week SMA near $0.74 and building a base for a potential breakout. The chart structure shows that ADA has a serious chance of targeting the $1.25 and $1.50 resistance levels if momentum continues to build. Both levels have acted as key rejection points in the past, and reclaiming them would mark a shift in sentiment after months of consolidation.

    Cardano Price Outlook Ahead of September Decisions

    ADA holds steady above key support, with analysts eyeing $1.25 and $1.50 targets as September’s macro decisions approach. Source: Ssebi via X

    Analyst Ssebi notes that factors such as possible rate cuts and ETF developments could provide the push ADA needs to move higher. With the RSI sitting around 53, there’s still room for upside before conditions become overheated, leaving space for a sustained rally.

    Cardano Clears Key Moving Averages

    Cardano has now managed to push above the 7, 25, and 99-week moving averages, a technical alignment that hasn’t been seen since its last major cycle run. This kind of structure often signals that momentum is shifting in favor of the bulls.

    Cardano Clears Key Moving Averages

    ADA flips above the 7, 25, and 99-week moving averages, signaling bullish momentum not seen since its last major cycle run. Source: TapTools via X

    Trading above all three layers suggests that ADA is beginning to establish a stronger floor, reducing the downside risk that has dominated in past months.

    TapTools highlights how this flip across multiple moving averages could serve as an early indication of broader trend continuation. Historically, ADA’s most explosive moves have come after clearing the 99-week MA, as it tends to act as the line between extended bearish phases and fresh bullish legs.

    $0.84 As The Breakout Confirmation Level

    Despite all the bullish developments, $0.84 remains the key level to confirm a true breakout for Cardano. Price is compressing inside a falling wedge, and the upper wedge boundary currently intersects near $0.84. A clean move and close above that line would flip the pattern and signal a shift from corrective action to trend continuation.

    $0.84 As The Breakout Confirmation Level

    Cardano ADA faces a decisive test at $0.84, with a breakout above the falling wedge seen as the trigger for a move towards $0.90–$0.95. Source: Ali Martinez via X

    As Ali Martinez highlights, a decisive break of the wedge top around $0.84 would open room towards $0.90 to $0.95 area. If bulls can reclaim and hold above the breakout level, it would neatly align with ADA’s recent moving-average flips and the broader altseason backdrop, turning $0.84 from ceiling into support.

    Final Thoughts

    Cardano is at an important turning point, where technicals and market sentiment are starting to align in its favor. The break above long-term moving averages, combined with the broader setup of a falling wedge, shows that momentum is quietly building under the surface.

    If buyers manage to flip $0.84 into support, it would not only confirm the breakout but also strengthen the case for ADA pushing towards $0.90 and beyond. In a market leaning towards altseason, this type of confirmation could act as the spark that shifts Cardano back into the spotlight.



    Source link

    Go to Top